
1. bmc immunol. 2015 mar 26;16:14. doi: 10.1186/s12865-015-0078-z.

the genetic control immunity plasmodium infection.

grant av(1)(2), roussilhon c(3)(4), paul r(5)(6), sakuntabhai a(7)(8).

author information: 
(1)unité de la génétique fonctionnelle des maladies infectieuses, institut
pasteur, paris, france. audrey.grant@pasteur.fr.
(2)centre national de la recherche scientifique, ura3012, paris, france.
audrey.grant@pasteur.fr.
(3)unité de la génétique fonctionnelle des maladies infectieuses, institut
pasteur, paris, france. roussilo@pasteur.fr.
(4)centre national de la recherche scientifique, ura3012, paris, france.
roussilo@pasteur.fr.
(5)unité de la génétique fonctionnelle des maladies infectieuses, institut
pasteur, paris, france. richard.paul@pasteur.fr.
(6)centre national de la recherche scientifique, ura3012, paris, france.
richard.paul@pasteur.fr.
(7)unité de la génétique fonctionnelle des maladies infectieuses, institut
pasteur, paris, france. anavaj@pasteur.fr.
(8)centre national de la recherche scientifique, ura3012, paris, france.
anavaj@pasteur.fr.

background: malaria remains major worldwide public health problem ~207
million cases ~627,000 deaths per year, mainly affecting children five 
years age africa. recent efforts elaborating genetic architecture of
malaria focused severe malaria, leading identification two new 
genes confirmation previously known variants hbb, abo g6pd, by
exploring whole human genome genome-wide association (gwa) studies.
molecular pathways controlling phenotypes representing effectiveness host
immunity, notably parasitemia igg levels, particular interest given
the current lack efficacious vaccine need new treatment
options.
results: propose global causal framework malaria phenotypes implicating
progression initial infection plasmodium spp. development of
the infection liver blood-stage multiplication cycles (parasitemia as
a quantitative trait), clinical malaria attack, finally severe malaria.
genetic polymorphism may control stages, preceding stages 
act mediators subsequent stages. biomarker humoral immunity, igg
levels, also integrated framework, potentially mediating the
impact polymorphism limiting parasitemia levels. current knowledge the
genetic basis parasitemia levels igg levels reviewed key
examples including hemoglobinopathies, showing protective effect 
hbb variants malaria clinical phenotypes may partially mediated through
parasitemia cytophilic igg levels. another example igg receptor
fcγriia, encoded fcgr2a, h131 homozygotes displayed higher igg2
levels protective high parasitemia onset malaria symptoms
as shown causal diagram.
conclusions: thus underline value parasitemia igg levels as
phenotypes understanding human genetic architecture malaria, and
the need applying gwa approaches phenotypes.

doi: 10.1186/s12865-015-0078-z 
pmcid: pmc4374205
pmid: 25887595  [indexed medline]

